{"id":5547,"date":"2024-02-08T01:21:00","date_gmt":"2024-02-08T01:21:00","guid":{"rendered":"https:\/\/economicherald.net\/?p=5547"},"modified":"2024-02-08T01:21:00","modified_gmt":"2024-02-08T01:21:00","slug":"asx-health-stocks-cochlear-upgrades-guidance-chimeric-up-12pc-after-commencing-phase-1b-trial-on-leukaemia","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=5547","title":{"rendered":"ASX Health Stocks: Cochlear upgrades guidance, Chimeric up 12pc after commencing Phase 1B trial on leukaemia"},"content":{"rendered":"<p>Cochlear upgrades guidance after strong H1<br \/>\nChimeric doses first patient in Phase 1B clinical trial<br \/>\nTelix acquires US company, QSAM, to advance cancer program<\/p>\n<p>\u00a0<\/p>\n<h2>Cochlear upgrades guidance<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/cochlear-coh\/\">Cochlear (ASX:COH)<\/a><\/strong> rose +6% this morning after upgrading its FY24 earnings guidance.<\/p>\n<p>The company said that following the better than expected first half revenue for Cochlear implants, underlying net profit for FY24 is now expected to be $385-400 million, a 26-31% increase on FY23.<\/p>\n<p>The upgrade is 8% above the midpoint of the prior guidance of $355-375 million advised in August last year.<\/p>\n<p>\u201cCochlear implant trading conditions have been strong across the first half, with units growing 14%,\u201d said<em> CEO &amp; president Dig Howitt.<\/em><\/p>\n<p>\u201cWe have maintained the market share gains made in FY23 and market growth has continued to be robust across both developed and emerging markets, as well as all age segments \u2013 children, adults and seniors.\u201d<\/p>\n<p>\u00a0<\/p>\n<h2>Chimeric does first patient in Phase 1, leukaemia trial<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/chimeric-therapeutics-chm\/\">Chimeric Therapeutics (ASX:CHM)<\/a><\/strong> surged 12% this morning after announcing that the first patient in the <strong>ADVENT-AML Phase 1B clinical trial<\/strong> in <strong>Acute Myeloid Leukaemia (AML)<\/strong> has received treatment with CHM 0201, in combination with<em> Azacitidine<\/em> and <em>Venetoclax<\/em>.<\/p>\n<p>The study is the first trial to evaluate the synergy of Chimeric\u2019s NK cell therapy in combination with the current standard of care for AML, Azacitidine and Venetoclax.<\/p>\n<p>The study is designed to enroll up to 20 subjects with newly diagnosed AML, who are not eligible for intensive chemotherapy or allogeneic stem cell transplant.<\/p>\n<p>\u201cThe novel combination of CHM 0201 with the standard of care in AML treatment has the potential to transform frontline therapy and enhance outcomes for AML patients,\u201d said <em>Jason B Litten MD, chief medical officer of Chimeric.<\/em><\/p>\n<p>CHM 1101 (CLTX CAR T) is a novel CAR T therapy developed for the treatment of patients with solid tumours.<\/p>\n<p>Positive preliminary data from the investigator-initiated Phase 1A trial in glioblastoma was already announced in October 2023.<\/p>\n<p>\u00a0<\/p>\n<h2>Telix buys QSAM<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/telix-pharmaceuticals-tlx\/\">Telix Pharmaceuticals (ASX:TLX)<\/a><\/strong> has entered into an agreement to acquire <strong>QSAM Biosciences<\/strong>, and its lead investigational drug <strong>Samarium-153-DOTMP (153Sm-DOTMP)<\/strong>.<\/p>\n<p>QSAM is a US based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.<\/p>\n<p>The purchase price comprises US$33.1 million ($50.8 million) upfront, which is payable in the form of Telix shares.<\/p>\n<p>On top of that, there are performance-based payments, which will require Telix to pay contingent payments up to US$90 million ($138 million) in total, payable in cash and\/or in ordinary shares, upon achievement of certain clinical and commercial milestones.<\/p>\n<p><em>Group CEO of Telix, Dr Christian Behrenbruch<\/em>, said the acquisition of QSAM will provide Telix with an additional near-term therapeutic pipeline, and further differentiate its position in radiopharmaceuticals.<\/p>\n<p>In the US, there are over 400,000 new patients diagnosed each year with metastatic bone cancer and 350,000 patient deaths.<\/p>\n<p>\u00a0<\/p>\n<h2>Share prices today:<\/h2>\n<p>\u00a0<\/p>\n\n<p><span class=\"mce_SELRES_start\">\ufeff<\/span><span class=\"mce_SELRES_start\"><\/span>\u00a0<br \/>\n<span class=\"et_bloom_bottom_trigger\"><\/span><\/p>\n<p>The post <a href=\"https:\/\/stockhead.com.au\/health\/asx-health-stocks-cochlear-upgrades-guidance-chimeric-up-12pc-after-commencing-phase-1b-trial-on-leukaemia\/\">ASX Health Stocks: Cochlear upgrades guidance, Chimeric up 12pc after commencing Phase 1B trial on leukaemia<\/a> appeared first on <a href=\"https:\/\/stockhead.com.au\/\">Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>Cochlear upgrades guidance after strong H1 Chimeric doses first patient in Phase 1B clinical trial Telix acquires US company, QSAM, to advance cancer program \u00a0 <a href=\"https:\/\/economicherald.net\/?p=5547\" class=\"read-more-link\">[more&#8230;]<\/a><\/p>\n","protected":false},"author":0,"featured_media":5548,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-5547","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASX Health Stocks: Cochlear upgrades guidance, Chimeric up 12pc after commencing Phase 1B trial on leukaemia - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=5547\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: Cochlear upgrades guidance, Chimeric up 12pc after commencing Phase 1B trial on leukaemia - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"Cochlear upgrades guidance after strong H1 Chimeric doses first patient in Phase 1B clinical trial Telix acquires US company, QSAM, to advance cancer program \u00a0 [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=5547\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-08T01:21:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/02\/Cochlear-upgrades-guidance-after-strong-H1.-Picture-Getty-Gsmey2.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5547#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5547\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: Cochlear upgrades guidance, Chimeric up 12pc after commencing Phase 1B trial on leukaemia\",\"datePublished\":\"2024-02-08T01:21:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5547\"},\"wordCount\":494,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5547#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Cochlear-upgrades-guidance-after-strong-H1.-Picture-Getty-Gsmey2.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=5547#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5547\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=5547\",\"name\":\"ASX Health Stocks: Cochlear upgrades guidance, Chimeric up 12pc after commencing Phase 1B trial on leukaemia - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5547#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5547#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Cochlear-upgrades-guidance-after-strong-H1.-Picture-Getty-Gsmey2.jpeg\",\"datePublished\":\"2024-02-08T01:21:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5547#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=5547\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5547#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Cochlear-upgrades-guidance-after-strong-H1.-Picture-Getty-Gsmey2.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Cochlear-upgrades-guidance-after-strong-H1.-Picture-Getty-Gsmey2.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5547#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: Cochlear upgrades guidance, Chimeric up 12pc after commencing Phase 1B trial on leukaemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: Cochlear upgrades guidance, Chimeric up 12pc after commencing Phase 1B trial on leukaemia - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=5547","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: Cochlear upgrades guidance, Chimeric up 12pc after commencing Phase 1B trial on leukaemia - Economic Herald","og_description":"Cochlear upgrades guidance after strong H1 Chimeric doses first patient in Phase 1B clinical trial Telix acquires US company, QSAM, to advance cancer program \u00a0 [more...]","og_url":"https:\/\/economicherald.net\/?p=5547","og_site_name":"Economic Herald","article_published_time":"2024-02-08T01:21:00+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/02\/Cochlear-upgrades-guidance-after-strong-H1.-Picture-Getty-Gsmey2.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=5547#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=5547"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: Cochlear upgrades guidance, Chimeric up 12pc after commencing Phase 1B trial on leukaemia","datePublished":"2024-02-08T01:21:00+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=5547"},"wordCount":494,"commentCount":0,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=5547#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/02\/Cochlear-upgrades-guidance-after-strong-H1.-Picture-Getty-Gsmey2.jpeg","articleSection":["Finance"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/economicherald.net\/?p=5547#respond"]}]},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=5547","url":"https:\/\/economicherald.net\/?p=5547","name":"ASX Health Stocks: Cochlear upgrades guidance, Chimeric up 12pc after commencing Phase 1B trial on leukaemia - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=5547#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=5547#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/02\/Cochlear-upgrades-guidance-after-strong-H1.-Picture-Getty-Gsmey2.jpeg","datePublished":"2024-02-08T01:21:00+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=5547#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=5547"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=5547#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/02\/Cochlear-upgrades-guidance-after-strong-H1.-Picture-Getty-Gsmey2.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/02\/Cochlear-upgrades-guidance-after-strong-H1.-Picture-Getty-Gsmey2.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=5547#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: Cochlear upgrades guidance, Chimeric up 12pc after commencing Phase 1B trial on leukaemia"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/5547","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5547"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/5547\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/5548"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}